179 related articles for article (PubMed ID: 22939523)
21. Comparative mutant prevention concentration and mechanism of resistance to veterinary fluoroquinolones in Staphylococcus pseudintermedius.
Awji EG; Tassew DD; Lee JS; Lee SJ; Choi MJ; Reza MA; Rhee MH; Kim TH; Park SC
Vet Dermatol; 2012 Aug; 23(4):376-80, e68-9. PubMed ID: 22409306
[TBL] [Abstract][Full Text] [Related]
22. A seven-year survey of susceptibility to marbofloxacin of pathogenic strains isolated from pets.
Meunier D; Acar JF; Martel JL; Kroemer S; Valle M
Int J Antimicrob Agents; 2004 Dec; 24(6):592-8. PubMed ID: 15555883
[TBL] [Abstract][Full Text] [Related]
23. Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of Escherichia coli from dogs.
Gebru E; Damte D; Choi MJ; Lee SJ; Kim YH; Park SC
Vet Microbiol; 2012 Jan; 154(3-4):384-94. PubMed ID: 21893387
[TBL] [Abstract][Full Text] [Related]
24. Bactericidal properties of pradofloxacin against veterinary pathogens.
Silley P; Stephan B; Greife HA; Pridmore A
Vet Microbiol; 2012 May; 157(1-2):106-11. PubMed ID: 22209121
[TBL] [Abstract][Full Text] [Related]
25. Antimicrobial resistance and novel mutations detected in the gyrA and parC genes of Pseudomonas aeruginosa strains isolated from companion dogs.
Park Y; Oh J; Park S; Sum S; Song W; Chae J; Park H
BMC Vet Res; 2020 Apr; 16(1):111. PubMed ID: 32293442
[TBL] [Abstract][Full Text] [Related]
26. In vitro antimicrobial activity of marbofloxacin and enrofloxacin against bacterial strains isolated from companion animals.
Farca AM; Cavana P; Robino P; Nebbia P
Schweiz Arch Tierheilkd; 2007 Jun; 149(6):265-71. PubMed ID: 17645036
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamics of ibafloxacin in micro-organisms isolated from cats.
Coulet M; Cox P; Lohuis J
J Vet Pharmacol Ther; 2005 Feb; 28(1):29-36. PubMed ID: 15720512
[TBL] [Abstract][Full Text] [Related]
28. Pradofloxacin: a novel veterinary fluoroquinolone for treatment of bacterial infections in cats.
Sykes JE; Blondeau JM
Vet J; 2014 Aug; 201(2):207-14. PubMed ID: 24997792
[TBL] [Abstract][Full Text] [Related]
29. Antibiotic susceptibility of bacteria isolated from infections in cats and dogs throughout Europe (2002-2009).
Kroemer S; El Garch F; Galland D; Petit JL; Woehrle F; Boulouis HJ
Comp Immunol Microbiol Infect Dis; 2014 Mar; 37(2):97-108. PubMed ID: 24447508
[TBL] [Abstract][Full Text] [Related]
30. Antimicrobial activity and spectrum of cefovecin, a new extended- spectrum cephalosporin, against pathogens collected from dogs and cats in Europe and North America.
Stegemann MR; Passmore CA; Sherington J; Lindeman CJ; Papp G; Weigel DJ; Skogerboe TL
Antimicrob Agents Chemother; 2006 Jul; 50(7):2286-92. PubMed ID: 16801403
[TBL] [Abstract][Full Text] [Related]
31. Detection of fluoroquinolone resistance level in clinical canine and feline Escherichia coli pathogens using rapid real-time PCR assay.
Shaheen BW; Wang C; Johnson CM; Kaltenboeck B; Boothe DM
Vet Microbiol; 2009 Nov; 139(3-4):379-85. PubMed ID: 19596530
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics, pharmacodynamics and therapeutics of pradofloxacin in the dog and cat.
Lees P
J Vet Pharmacol Ther; 2013 Jun; 36(3):209-21. PubMed ID: 23406008
[TBL] [Abstract][Full Text] [Related]
33. Characterization of quinolone resistance mechanisms in Enterobacteriaceae recovered from diseased companion animals in Europe.
Guillard T; de Jong A; Limelette A; Lebreil AL; Madoux J; de Champs C;
Vet Microbiol; 2016 Oct; 194():23-29. PubMed ID: 26701806
[TBL] [Abstract][Full Text] [Related]
34. A pilot study on the comparative minimum inhibitory and mutant prevention concentration values for moxifloxacin and pradofloxacin against canine and human isolates of Staphylococcus pseudintermedius and S. schleiferi.
Plowgian C; Blondeau JM; Levinson M; Rosenkrantz W
Vet Dermatol; 2019 Dec; 30(6):481-e142. PubMed ID: 31486554
[TBL] [Abstract][Full Text] [Related]
35. Comparative in vitro killing of canine strains of Staphylococcus pseudintermedius and Escherichia coli by cefovecin, cefazolin, doxycycline and pradofloxacin.
Blondeau JM; Shebelski SD
Vet Dermatol; 2016 Aug; 27(4):267-e63. PubMed ID: 27307405
[TBL] [Abstract][Full Text] [Related]
36. Antimicrobial resistance and genetic characterization of fluoroquinolone resistance of Pseudomonas aeruginosa isolated from canine infections.
Rubin J; Walker RD; Blickenstaff K; Bodeis-Jones S; Zhao S
Vet Microbiol; 2008 Sep; 131(1-2):164-72. PubMed ID: 18395369
[TBL] [Abstract][Full Text] [Related]
37. In vitro killing of Escherichia coli, Staphylococcus pseudintermedius and Pseudomonas aeruginosa by enrofloxacin in combination with its active metabolite ciprofloxacin using clinically relevant drug concentrations in the dog and cat.
Blondeau JM; Borsos S; Blondeau LD; Blondeau BJ
Vet Microbiol; 2012 Mar; 155(2-4):284-90. PubMed ID: 21925810
[TBL] [Abstract][Full Text] [Related]
38. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.
Moon DC; Seol SY; Gurung M; Jin JS; Choi CH; Kim J; Lee YC; Cho DT; Lee JC
Int J Antimicrob Agents; 2010 Jan; 35(1):76-9. PubMed ID: 19781915
[TBL] [Abstract][Full Text] [Related]
39. Comparative quantification of the in vitro activity of veterinary fluoroquinolones.
Grobbel M; Lübke-Becker A; Wieler LH; Froyman R; Friederichs S; Filios S
Vet Microbiol; 2007 Sep; 124(1-2):73-81. PubMed ID: 17498893
[TBL] [Abstract][Full Text] [Related]
40. Mutant-prevention concentration and mechanism of resistance in clinical isolates and enrofloxacin/marbofloxacin-selected mutants of Escherichia coli of canine origin.
Gebru E; Choi MJ; Lee SJ; Damte D; Park SC
J Med Microbiol; 2011 Oct; 60(Pt 10):1512-1522. PubMed ID: 21596912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
